PetVivo Holdings, Inc. to Exhibit at American Association of Equine Practitioners Conference in Nashville, Tennessee
November 30 2021 - 11:00AM
PetVivo Holdings, Inc. (NASDAQ: PETV) (the "Company") an emerging
biomedical device company focused on the commercialization of
innovative medical therapeutics for pets announced today it will be
exhibiting at the American Association Equine Practitioners
(“AAEP”) conference to be held December 4th to December 8th, 2021
at the Music City Center in Nashville, Tennessee.
PetVivo intends to introduce its lead product,
SPRYNG™ with OsteoCushion™ Technology, a medical device injection
of sterilized, extra-cellular matrix microparticles that are
lubricious and spongy used in the treatment of lameness and other
joint related afflictions, such as osteoarthritis. The AAEP is the
largest veterinary equine conference that services the United
States, and normally plays host to more than 5,000 participants
including many of the top industry professionals.
“We are looking forward to networking with
leaders in the industry and develop relationships that will help
drive forward our initial veterinary medical device, SPRYNG, for
the management of lameness issues, including conditions related to
osteoarthritis, in our family members and equine athletes,” said
John Lai, Chief Executive Officer of PetVivo Holdings, Inc.
For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit https://petvivo.com/
Conference Exhibit Details:
American Association of Equine Practitioners
Conference (AAEP)
Booth #: 211
Dates:
Sunday, December 5, 2021 10:00am – 6:00pm
Monday, December 6, 2021 10:00am – 6:00pm
Tuesday, December 7, 2021 10:00am – 2:00pm
Location: Music City Center in Nashville,
Tennessee.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an
emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of twenty-one
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG, a
veterinarian-administered, intraarticular injection for the
treatment of lameness and other joint related afflictions,
including osteoarthritis, in dogs and horses, is scheduled for
expanded commercial sale in the fourth quarter of this year.
CONTACT:
John Lai, CEOPetVivo Holdings, Inc.Email: info1@petvivo.com(952)
405-6216
Forward-Looking commercial Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements,
including the potential listing of the Company’s common stock on
Nasdaq, are based on information currently available the Company
and its current plans or expectations and are subject to a number
of uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2021 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From Aug 2024 to Sep 2024
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From Sep 2023 to Sep 2024